TUSC2 overexpression and erlotinib treatment demonstrate an additive effect, suppressing NSCLC both in vitro and in vivo, and co-administration of TUSC2 and erlotinib decreased tumor growth and metastasis, and increased apoptosis compared to controls or single agent treatment [75]. The gene discussed is TUSC2; the disease is neoplasm.